Dr. Osamu Ishiba]shi received his M.S. from
Tokyo Institute of Technology (Japan) in 1993. In the same year, he joined a pharmaceutical
company, Ciba-Geigy Japan (currently Novartis Pharma), and conducted basic
research leading to the development of novel antiosteoporosis drugs, including
cathepsin K inhibitors. Based on the achievements in the company, he received
his Ph.D from Nagaoka University of Technology (Japan) in 2000. He then
accepted academic positions including a postdoctoral fellow with the Max-Planck
Institute of Biochemistry (Germany) and as a senior scientist in Niigata
University (Japan). In 2006, he joined Nippon Medical School as a senior assistant
professor and started new projects focused on the microRNA-mediated regulation of cell
functions. In 2012, he accepted his current position (associate professor) with
Osaka Prefecture University (Osaka Metropolitan University since 2022) to
conduct studies on genome-wide transcriptomics associated with pathology
including cancer and kidney diseases.
Dr. Ishibashi has published more than 60
publications in international peer-review journals. He also serves as an
editorial board member or associate editor for a number of journals.
Dr. Osamu Ishiba]shi received his M.S. from
Tokyo Institute of Technology (Japan) in 1993. In the same year, he joined a pharmaceutical
company, Ciba-Geigy Japan (currently Novartis Pharma), and conducted basic
research leading to the development of novel antiosteoporosis drugs, including
cathepsin K inhibitors. Based on the achievements in the company, he received
his Ph.D from Nagaoka University of Technology (Japan) in 2000. He then
accepted academic positions including a postdoctoral fellow with the Max-Planck
Institute of Biochemistry (Germany) and as a senior scientist in Niigata
University (Japan). In 2006, he joined Nippon Medical School as a senior assistant
professor and started new projects focused on the microRNA-mediated regulation of cell
functions. In 2012, he accepted his current position (associate professor) with
Osaka Prefecture University (Osaka Metropolitan University since 2022) to
conduct studies on genome-wide transcriptomics associated with pathology
including cancer and kidney diseases.
Dr. Ishibashi has published more than 60
publications in international peer-review journals. He also serves as an
editorial board member or associate editor for a number of journals.